

## A systematic dissection of human primary osteoblasts *in vivo* at single-cell resolution

Yun Gong<sup>1§</sup>, Junxiao Yang<sup>2§</sup>, Xiaohua Li<sup>3</sup>, Cui Zhou<sup>3</sup>, Yu Chen<sup>3</sup>, Zun Wang<sup>6</sup>, Xiang Qiu<sup>5</sup>, Ying Liu<sup>3</sup>, Huixi Zhang<sup>3</sup>, Jonathan Greenbaum<sup>1</sup>, Liang Cheng<sup>7</sup>, Yihe Hu<sup>2</sup>, Jie Xie<sup>2</sup>, Xuecheng Yang<sup>2</sup>, Yusheng Li<sup>2</sup>, Yuntong Bai<sup>8</sup>, Yu-Ping Wang<sup>8</sup>, Yiping Chen<sup>9</sup>, Li-Jun Tan<sup>3</sup>, Hui Shen<sup>1</sup>, Hong-Mei Xiao<sup>4,5\*</sup>, Hong-Wen Deng<sup>1,5\*</sup>

1. Tulane Center for Bioinformatics and Genomics, Department of Biostatistics and Data Science, School of Public Health and Tropical Medicine, Tulane University, New Orleans, 70112, USA
2. Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China
3. Laboratory of Molecular and Statistical Genetics, College of Life Sciences, Hunan Normal University, Changsha, 410081, China
4. Center of Reproductive Health, System Biology and Data Information, Institute of Reproductive & Stem Cell Engineering, School of Basic Medical Science, Central South University, Changsha, 410081, China
5. School of Basic Medical Science, Central South University, Changsha, 410008, China
6. Xiangya Nursing School, Central South University, Changsha, 410013, China
7. Department of Orthopedics and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, China
8. Tulane Center for Bioinformatics and Genomics, Department of Biomedical Engineering, Tulane University, New Orleans, 70112, USA
9. Department of Cell and Molecular Biology, School of Science and Engineering, Tulane University, New Orleans, LA 70112, USA

§ These authors contributed equally to this work

**\*Corresponding author**

Hong-Wen Deng, Ph.D.

Professor

Director, Tulane Center for Bioinformatics and Genomics

Department of Biostatistics and Data Science

School of Public Health and Tropical Medicine, Tulane University

1440 Canal St., Suite 1610, New Orleans, LA 70112, USA

Tel: 504-988-1310,

Email: [hdeng2@tulane.edu](mailto:hdeng2@tulane.edu)

Hong-Mei Xiao, M.D., Ph.D.

Human Genetics and Reproductive Medicine

School of Basic Medical Science

Central South University (China)

173 Tongzipo Rd., Changsha, 70118, China

E-mail: [hmxiao@csu.edu.cn](mailto:hmxiao@csu.edu.cn)

## Abstract

Osteoblasts are multifunctional bone cells, which play essential roles in bone formation, angiogenesis regulation, as well as maintenance of hematopoiesis. Although both *in vivo* and *in vitro* studies on mice have identified several potential osteoblast subtypes based on their different transition stages or biological responses to external stimuli, the categorization of primary osteoblast subtypes *in vivo* in humans has not yet been achieved. Here, we used single-cell RNA sequencing (scRNA-seq) to perform a systematic cellular taxonomy dissection of freshly isolated human osteoblasts. Based on the gene expression patterns and cell lineage reconstruction, we identified three distinct cell clusters including preosteoblasts, mature osteoblasts, and an undetermined rare osteoblast subpopulation. Trajectory inference analysis suggested that the undetermined cluster include osteoblast precursor cells that regulate osteoblastogenesis as well as give rise to pre- and mature osteoblasts. Investigation of the biological processes and signaling pathways enriched in each subpopulation revealed that in addition to bone formation, pre- and undetermined osteoblasts may regulate both angiogenesis and hemopoiesis. Our findings provide novel insights into the cellular heterogeneity and potential biological functions of human primary osteoblasts at the single-cell level, which is an important and necessary step to further dissect the biological roles of osteoblasts in bone metabolism under various (patho-)physiological conditions.

Key words: single-cell RNA sequencing (scRNA-seq); osteoblasts; cellular heterogeneity; bone formation; angiogenesis; hemopoiesis

## Introduction

Osteoblasts, which account for 4-6% of resident cells in bone, are derived from pluripotent bone marrow mesenchymal stem cells (BMMSCs) through the activation of signaling pathways regulated by osterix (OSX) and Runt-related transcription factor 2 (Runx-2)<sup>1-4</sup>. These cells are primarily known for their bone-building functions, including deposition of calcium phosphate crystals (e.g. hydroxyapatite) and production of bone matrix constituents (e.g. type I collagen), as well as their ability to secrete a number of important proteins for bone metabolic processes such as integrin-binding sialoprotein (IBSP), secreted phosphoprotein 1 (SPP1), and bone gamma-carboxyglutamic acid-containing protein (BGLAP)<sup>5,6</sup>. In general, osteoblasts play a crucial role in the mineralization of the bone matrix<sup>7,8</sup>. Many osteoblasts differentiate into osteocytes, which become embedded in the bone matrix to form a communication network for the regulation of bone formation and resorption. Osteoblasts and osteocytes may regulate the differentiation of osteoclasts, which are primarily involved in bone resorption activities<sup>9</sup>. For instance, osteoblasts can promote osteoclast proliferation by producing macrophage-colony stimulating factor (M-CSF)<sup>10,11</sup>. In addition, osteoblasts can produce the receptor activator of nuclear factor kappa-B ligand (RANKL) and osteoprotegerin (OPG) to activate osteoclasts through the RANKL/RANK/OPG pathway<sup>12</sup>. The dynamics between the major bone cells control the delicate balance of bone formation/resorption that is critical for maintaining bone health.

While osteoblasts are typically associated with bone remodeling processes, previous studies have demonstrated that they also have the ability to interact with immune cells via the regulation of hematopoietic stem cell (HSC) niches. Specifically, primary osteoblast lineage cells synthesize granulocyte colony-stimulating factor (G-CSF), granulocyte M-CSF (GM-CSF), IL-1, IL-6, lymphotoxin, TGF $\beta$ , TNF $\alpha$ , leukemia inhibitory factor (LIF), and stem cell factor (SCF), all of which play crucial roles in hematopoiesis<sup>13-23</sup>. Additionally, osteoblasts are responsible for modulating angiogenesis, which supports the high degree of vascularization in the bone marrow environment to provide sufficient oxygen for bone metabolism<sup>24</sup>.

Cellular heterogeneity is an essential characteristic of tissues of various cell populations.

Although every cell shares almost the same genome, each cell acquires a unique identity and thus specific functional capabilities through molecular coding across the DNA, RNA, and protein

conversions<sup>25</sup>. Therefore, even for the same known classical cell types, cells may be further classified into distinct subpopulations due to these systematic differences. The cell subtypes contributing to cellular heterogeneity may be identified by differences in gene expression profiles. Several researches have proposed that the cell-to-cell heterogeneity exists in osteoblast populations by *in vitro* studies in mice. For instance, one study performed the soft agarose cloning technique on rat osteoblastic cells and detected diverse gene expression patterns in osteoblast cells at different stages of cell differentiation<sup>26</sup>. Another study showed that the expression levels of osteoblastic specific markers including osteopontin, bone sialoprotein, and osteocalcin, varied in the mature osteoblasts of mice with different cellular morphology, suggesting that even these terminally differentiated osteoblasts were composed of multiple subgroups instead of a single unique cell group<sup>27</sup>.

With the evidence for cell heterogeneity in osteoblasts, the state-of-the-art single-cell RNA sequencing (scRNA-seq) technology may provide the most powerful approach to study the nature and characteristics of cell-to-cell heterogeneity. Compared with the conventional bulk RNA-seq approaches, single-cell RNA sequencing can reveal complex and rare cell populations, track the trajectories of distinct cell lineages in development, and identify novel regulatory relationships between genes<sup>28</sup>. Recently, a few *in vivo* studies have applied scRNA-seq on the osteoblasts from mice. Baryawno et al.<sup>29</sup> identified the pre- and mature osteoblast subpopulations based on their transcriptional profiles, while Tikhonova et al.<sup>30</sup> classified the osteoblasts into three subgroups and revealed significant changes in subgroup proportions under stress conditions. Although our understanding of osteoblast heterogeneity has evolved substantially based on these studies, the cell subtype characteristics of primary osteoblasts *in vivo* in humans has not been explored. Studying the cellular heterogeneity in mice, or even the cultured cells from humans (though not existing yet), although useful, may not be ideal for studying human disease etiology. This is because the cell identity may vary between mice and humans, and cell culturing may systematically alter the gene expression of the studied cells<sup>31</sup>.

In this study, we performed the first unbiased examination of the *in vivo* cellular landscape of freshly isolated human osteoblasts via scRNA-seq. We identified three distinct cell subtypes along with their differentiation relationships based on the transcriptional profiling of 5,329

osteoblast cells from the femur head of one human subject. We compared the most differentially expressed genes (DEGs) of each cluster with known cell characterizing markers. We then identified distinct functional characteristics of each cell subpopulation (cluster) in bone metabolism, angiogenesis modulation, as well as hematopoietic stem cells (HSC) niche regulation. The discovery of osteoblast subtypes is well beyond the scope of current gene expression studies for bone health and represents an important and necessary step to provide novel insights into bone physiological processes at the refined single-cell level.

## Results

### Osteoblasts identification

We applied an established protocol for *in vivo* human osteoblast isolation<sup>32</sup> to obtain the alkaline phosphatase (ALPL)<sup>high</sup>/CD45/34/31<sup>low</sup> cells from the femur head-derived bone tissue of one human subject (31-year-old Chinese male) with osteoarthritis and osteopenia through fluorescence-activated cell sorting (FACS). Several studies<sup>33,34</sup> have demonstrated that this isolation protocol can successfully recover a high proportion of osteoblasts based on the high expression levels of osteoblastic markers via quantitative polymerase chain reaction (qPCR) or bulk RNA sequencing. In total, 9,801 single cells were encapsulated for cDNA synthesis and barcoded using the 10x Genomics Chromium system, followed by library construction and sequencing (**Figure 1A and Figure S1A**). After quality control, we obtained 8,557 cells, with an average of 1,503 genes detected per cell. A latest dimension reduction method for scRNA-seq analysis, uniform manifold approximation and projection (UMAP)<sup>35</sup>, was applied to project the gene expression profile on a two-dimension panel for visualization of cellular heterogeneity (**Figure S1B**). After clustering the cells into six distinct subsets (C1-C6) by the k-nearest neighbor algorithm<sup>36</sup>, we used pairwise differential expression analysis for each cluster against all the others to identify the DEGs of each subtype (**Figure S1C**).

While the ALPL was enriched in clusters C1, C2 and C5, the osteoblast specific marker, RUNX2 (encoded by *RUNX2*)<sup>37</sup>, was highly enriched in clusters C1 and C2 but not in other clusters, suggesting the presence of contamination by other cell types during the isolation (**Figure S1D**). Based on the identified marker genes, the contaminant cells were classified as; 1) two nucleated erythrocyte groups (C3 and C4, expressing hemoglobin coding genes *HBB* and *HBA1*)<sup>38</sup>; 2) one

smooth muscle cell group (C5, expressing smooth muscle alpha (alpha)-2 actin coding gene, *ACTA2*, and *CNN1*, which is specific to differentiated mature smooth muscle cells)<sup>39,40</sup>; and 3) one neutrophil group (C6, expressing neutrophil related genes *S100A8* and *MMP9*)<sup>41,42</sup> (**Figure S1D**). These findings indicated that the protocol of human osteoblast isolation based on *ALPL*<sup>high</sup>/*CD45*/*34*/*31*<sup>low</sup> is not sufficient for specifically isolating osteoblasts alone, since *ALPL* is also highly enriched in other mesenchymal stem cell (MSC)-derived cells like vascular smooth muscle cells<sup>43</sup>. Also, by comparing the expression profiles between osteoblasts and contaminant cells, we found that the average fold change (avg\_FC) of alpha-1 type I collagen (*COL1A1*, encoded by *COL1A1*) was high (avg\_FC =4.497, **Table S1**), suggesting that the positive selection based on the combination of *ALPL* and *COL1A1* would be a more appropriate choice for human primary osteoblast isolation. While several studies<sup>30,44</sup> in mice have used *COL1A1* for osteoblast sorting, few (if any) studies have adopted this marker for human primary osteoblast isolation.

### scRNA-seq identifies multiple cell subtypes in human osteoblasts

To investigate the cellular diversity within osteoblasts, we extracted the clusters C1 and C2 (n=5,329 cells) with high expression levels of osteoblast related markers, i.e., *RUNX2* and *COL1A1*, for further analysis (**Figure S1D**). Based on transcriptional profiles, we identified three cell subtypes of osteoblasts (**Figure 1B-1D**) which were annotated as; 1) O1 (65.77%), preosteoblasts, with relative high expression levels of osteogenic BMMSC markers leptin receptor (encoded by *LEPR*)<sup>45</sup>, vascular cell adhesion molecule 1 (encoded by *VCAM1*)<sup>46</sup>, and matrix gla protein (MGP, encoded by *MGP*)<sup>47</sup>; 2) O2 (25.39%), mature osteoblasts, which showed highest expression levels of *COL1A1* (*COL1A1*) and osteogenesis-associated genes including *BGLAP* (also known as osteocalcin, encoded by *BGLAP*), *SPP1* (also known as osteopontin, encoded by *SPP1*), and *IBSP* (encoded by *IBSP*)<sup>48</sup>; 3) O3 (8.84%), undetermined osteoblasts, which not only expressed several BMMSC-associated genes (e.g., *LEPR*, *VCAM1*, and *MGP*) but also are distinguished from the other subtypes by distinctively expressing high levels of nuclear receptor subfamily 4 group A member 1 and 2 (encoded by *NR4A1* and *NR4A2*).

We examined the transcription profiles of the three distinct subtypes of osteoblasts and found that in addition to the cell markers, some bone development regulators were highly enriched in

the pre- and mature osteoblast clusters. For instance, preosteoblasts expressed insulin-like growth factor-binding protein 2 and 4 (IGFBP2 and IGFBP4, encoded by *IGFBP2* and *IGFBP4*) (**Figure 2A**). Previous studies have considered IGFBP2 as a stimulator for osteoblast differentiation through positive regulation of the AMP-activated protein kinase (AMPK)<sup>49</sup>, and demonstrated that IGFBP4 could stimulate adult skeletal growth in males<sup>50</sup>. Meanwhile, tenascin, a glycoprotein encoded by *TNC* that modulates osteoblast mineralization via matrix vesicles<sup>51</sup>, was highly enriched in mature osteoblasts. On the other hand, the cluster O3 showed high expression level of osteomodulin (OMD) (**Figure 2A**). It has been proposed that OMD induces endochondral ossification through PI3K signaling, which is an essential process for long bone formation<sup>52</sup>.

Apart from known markers or functional genes, there were also some novel genes enriched in the pre- and mature osteoblasts. For instance, preosteoblasts highly expressed secretory leukocyte protease inhibitor (encoded by *SLPI*), a serine protease inhibitor that promotes cell migration and proliferation while also suppresses the inflammatory response<sup>53</sup> (**Figure 2A**). A recent study suggested that SLPI promotes the differentiation of osteoblasts<sup>54</sup>. Additionally, myristoylated alanine rich protein kinase C substrate (MARCKS, encoded by *MARCKS*), which is the PKC $\delta$  effector modulating cathepsin K secretion and bone resorption in osteoclasts<sup>55</sup>, was also enriched in the preosteoblasts (**Figure 2A**). While previous studies proposed that this gene is highly enriched in nervous system processes<sup>56</sup>, few studies have reported its presence in osteoblasts. Remarkably, we also found that *CPE*, encoding carboxypeptidase E, was highly enriched in mature osteoblasts (**Figure 2A**). It has been shown that this gene has a high enrichment in mature osteoclasts compared with their precursors, and plays a role in RANKL-induced osteoclast differentiation<sup>57</sup>. It is plausible that apart from known osteoclastogenesis regulators including RANKL, OPG, and M-CSF<sup>10</sup>, *CPE* may be another essential factor produced by osteoblasts for modulating osteoclast development.

In contrast to the known osteoblast subtypes, the cluster O3 highly expressed orphan nuclear receptors coding genes *NR4A2* and *NR4A1*. Although only a few studies have reported the presence of these genes in osteoblasts<sup>58,59</sup>, their importance in bone remodeling has been previously suggested. It has been shown that the reduced expression of nuclear receptor-related 1



(NURR1, encoded by *NR4A2*) inhibits the expression of osteoblast differentiation marker genes such as *BGLAP* and *COL1A1*<sup>60</sup>. Meanwhile, nuclear receptor subfamily 4 group A member 1 (NR4A1, encoded by *NR4A1*) has been proposed to inhibit osteoclastogenesis by producing an enzyme that breaks down the nuclear factor of activated T-cells (NFATc1) protein<sup>61,62</sup>.

While all the osteoblast clusters highly expressed the osteoblastogenic gene *RUNX2*<sup>37</sup>, they may affect bone development from different aspects. To further investigate the distinct biological functions related to osteogenesis among the three clusters of osteoblasts, we performed gene ontology (GO) enrichment analysis based on the DEGs (avg\_FC > 1.200, **Table S2**) in each cluster. All the clusters were enriched in GO terms related to bone development including “extracellular matrix organization” and “extracellular structure organization” (**Figures 2B-2E**). The pre- and mature osteoblasts are involved in the extracellular matrix (ECM) formation through production of different types of collagen, such as types 3, 14, and 18 in preosteoblasts and types 1, 12, and 13 in mature osteoblasts (**Tables S3 and S4**). The mature osteoblasts were uniquely enriched for “bone mineralization”, while mature and undetermined osteoblasts were both enriched for “osteoblast differentiation” (**Figures 2C-2E, Tables S4 and S5**). Additionally, the undetermined osteoblasts were uniquely enriched for “regulation of osteoblast differentiation” and “positive regulation of osteoblast differentiation” (**Figure 2D**).

### **Dynamic gene expression patterns reveal the differentiation relationship between different clusters**

In order to reveal the differentiation dynamics of osteoblasts, we reconstructed the developmental trajectory of the three identified clusters of osteoblasts. All the cells were contained within one cellular lineage without any bifurcations (**Figure 3A**), suggesting that only one terminal subtype exists in the osteoblastic population. While preosteoblasts and undetermined osteoblasts were highly enriched in the early stages of pseudotime, mature osteoblasts were distributed in the terminal stages of the osteoblastic lineage (**Figure 3A**). To strengthen the trajectory inference, we also checked the transcriptional continuum of the cell lineage. The results showed that the expression of BMMSC associated genes, *LEPR* and *APOE*<sup>65</sup>, decreased over pseudotime, while the expression of osteogenic markers such as *RUNX2*, *ALPL*, *BGLAP*, *SPARC*<sup>66</sup>, and *COL1A1* were the highest at the end stages of pseudotime (**Figure 3B**).

This result is consistent with the findings from other studies that have examined the transcriptional continuum in osteoblastic differentiation<sup>67</sup>. We found that the proportion of preosteoblasts increases during the early stages of pseudotime, followed by a sharp decline in the mid- to late stages, whereas the proportion of mature osteoblasts rapidly increases in the mid- to late stages (**Figure 3C**). Interestingly, the proportion of undetermined osteoblasts steadily declines from the beginning to late stages (**Figure 3C**), suggesting that the undetermined osteoblasts may represent cells at the earliest stages of the osteoblastic lineage and give rise to pre-osteoblasts.

### **Preosteoblasts regulate angiogenesis through multiple signaling pathways**

Although evidence has shown that osteoblasts can regulate angiogenesis<sup>24,68</sup>, few studies have explored this relationship at the single-cell level. Based on functional enrichment of the highly expressed genes, we found that the GO term “regulation of angiogenesis” was enriched in preosteoblasts but not in the other clusters (**Figure 4A**). We further investigated the enriched genes in preosteoblasts and found that 22 genes are involved in angiogenesis (**Table S3**). In particular, the preosteoblasts showed significantly higher expression levels of *SFRP1*, *MDK*, and *THBS1* compared with the other clusters (**Figure 4B**). It has been demonstrated that Secreted Frizzled-related protein-1 (sFRP1, encoded by *SFRP1*), a modulator of Wnt/Fz pathway, can modify MSC capacities enabling MSCs to increase vessel maturation<sup>69</sup>. Midkine (MDK, encoded by *MDK*) is an enhancer of angiogenesis, which was suggested by positive correlation between MDK expression and vascular density in bladder tumors<sup>70</sup>. Thrombospondin 1 (THBS1, encoded by *THBS1*) is considered to be a potent endogenous inhibitor of angiogenesis through antagonization of vascular endothelial growth factor (VEGF) activity<sup>71</sup>. Next, we investigated the signaling pathways enriched in preosteoblasts that are related to angiogenesis. Kyoto encyclopedia of genes and genomes (KEGG) pathway analysis revealed three highly enriched pathways including PI3K-Akt, phospholipase D, and relaxin signaling pathways, which were implicated in angiogenesis modulation<sup>72-74</sup> (**Figure 4C**). Several genes related to the “regulation of angiogenesis” GO term were enriched in these pathways (**Table S3, Figure 4C**), including *COL4A2*, *TGFBR2*, and *IL7*. These findings provide evidence that preosteoblasts may regulate angiogenesis through multiple pathways, such as PI3K-Akt, phospholipase, and relaxin signaling pathways.

## Osteoblast populations modulate the development of HSC niche

Osteoblasts are parts of the stromal cell support system that provides critical regulators of hematopoiesis<sup>75</sup>. It has been reported that osteoblasts lining the bone surface can generate an extracellular environment supporting non-skeletal hematopoietic cells<sup>76</sup>. To identify the specific roles of each osteoblast subpopulation in hematopoiesis regulation, we first examined the expression patterns of hematopoiesis related factors in all the three clusters. We found that while both pre- and undetermined osteoblasts highly expressed insulin-like growth factor 1 (IGF-1, encoded by *IGF1*), which is a growth factor responsible of burst-like growth of early erythroid progenitor cells *in vitro*.<sup>77</sup>, the preosteoblasts also expressed high levels of M-CSF (encoded by *CSF1*), stem cell factor (SCF, encoded by *KITLG*), and interleukin 7 (IL-7, encoded by *IL7*) (**Figure 4D**). This result suggested that preosteoblasts represent a crucial osteoblast subpopulation that may modulate macrophages development<sup>78</sup>, prevent HSC apoptosis<sup>79</sup>, as well as regulate T-cells differentiation<sup>80</sup>. We also found that the undetermined osteoblasts represent a major source of C-C motif chemokine ligand 2 (CCL-2, encoded by *CCL2*) (**Figure 4D**), which is a critical factor for monocyte recruitment in acute inflammatory response<sup>81</sup>. In addition, the undetermined osteoblasts also expressed interleukin 6 (IL-6, encoded by *IL6*), which displays a strong synergy with IL-7 to stimulate naïve CD8<sup>+</sup> T cells<sup>82</sup>. Therefore, the undetermined osteoblasts may coordinate with preosteoblasts to support the hemopoietic niche. However, few hematopoietic factors were enriched in mature osteoblasts, suggesting that they may have limited impact on the hematopoietic system.

We investigated the predicted functions associated with hematopoiesis regulation enriched in the pre- and undetermined osteoblasts. Notably, while the GO term “positive regulation of hemopoiesis” was enriched in preosteoblasts, the highly expressed genes of the undetermined cluster were related to the negative regulation of hemopoiesis (**Figure 4A**). Apart from the growth factors mentioned above, preosteoblasts also had a significantly higher expression level of growth arrest-specific 6 (GAS6, encoded by *GAS6*) (**Figure 4D**), which can induce natural killer cell development via its positive regulatory effect on fibromyalgia syndrome-like tyrosine kinase 3 (FLT3) signaling in CD34<sup>+</sup> hematopoietic progenitor cells (HPCs)<sup>83</sup>. Meanwhile, the undetermined subgroup had significantly higher expression levels of zinc-finger protein 36

(ZFP36, encoded by *ZFP36*) (**Figure 4D**), which can inhibit the erythroid differentiation<sup>84</sup>.

These findings suggested that these two subgroups may play different roles in hemopoiesis regulation, and that the relative proportions and functional levels of these subtypes within the osteoblast cell population may be crucial for maintaining the homeostasis of hematopoiesis.

### **Transcriptional divergence of human and mouse osteoblasts at single-cell resolution**

Given the previous studies performed *in vivo* in mice with scRNA-seq, to better understand the differences in osteoblastic transcriptional profiles between humans and mice, we integrated our sequencing data with the publicly available data from a previous scRNA-seq study<sup>30</sup> on mouse osteoblasts (**Figure 5A**). After correcting for the potential batch effects between independent experiments using canonical correlation analysis (CCA)<sup>36</sup>, a moderate positive correlation ( $R = 0.53$ ,  $p\text{-value} < 2.23e-16$ ) was observed between the human and mouse osteoblastic transcriptomic profiles (**Figure 5B**). This result suggested that while some common characteristics may exist between human and mouse osteoblasts, there are considerable differences in the gene expression profiles between osteoblasts in humans and mice at the single-cell level.

To further investigate the shared and distinct features among human and mouse osteoblasts, we applied unbiased clustering analysis with UMAP<sup>35</sup> for dimension reduction. The result showed that human osteoblast cluster O2 overlapped with mouse osteoblast subtype M2, which represents the mature osteoblasts in mice<sup>30</sup> (**Figure 5A and 5C**), indicating that the overall gene expression patterns of human and mouse mature osteoblasts are highly similar. Furthermore, we also found strong correlations of the expression patterns between small subgroups in human preosteoblasts (cluster O1) and the mouse osteoblast subtype M1 (**Figure 5A and C**). In contrast, the human osteoblast cluster O3 did not overlap with any osteoblast subtypes in mice (**Figure 5A**). These findings suggested that the transcriptional profiles of human and mouse osteoblasts showed systematic differences in early cellular developmental stages but shared similar features at the terminal stage of osteoblastic development lineage. Therefore, studies based on osteoblasts acquired from mouse models may introduce notable bias when inferring the biological characteristics of human osteoblasts, especially for those that have not yet reached a mature state.

## Discussion

While it is now well-appreciated that human osteoblast heterogeneity may be distinguished by differentiations stages<sup>26</sup>, the full spectrum of cells that comprise the osteoblast population, especially *in vivo* in humans, has remained elusive. In this study, we, for the first time, characterized the freshly isolated primary osteoblasts without any *in vitro* culturing from human bone into three subpopulations based on systematic differences in gene expression profiles and revealed their potential differential roles in bone metabolism as well as in the regulation of angiogenesis and hemopoiesis. Further, our results along with previous evidence have emphasized that transcription profiles are not all the same between humans and mice, highlighting the importance of *in vivo* studies in humans.

Here, we highlight some of the key findings. First, our results indicated that the method typically used in the field<sup>32</sup> - FACS isolation based on ALPL was not sufficient for specific isolation of osteoblasts since the isolated cell population included approximately 40% contamination by the other cell types. By comparing the transcriptomic profiles between osteoblasts and contamination cells, we suggested that the combination of ALPL and COL1A1 in osteoblasts selection may be more appropriate to isolate more homogeneous osteoblasts. In addition to known osteoblast subtypes, pre- and mature osteoblasts, we identified one rare osteoblast subpopulation expressing NR4A1 and NR4A2. Based on the gene expression patterns and the inferred osteoblastic lineage trajectory, we found that: 1) undetermined osteoblasts (NR4A1<sup>high</sup>/NR4A2<sup>high</sup>) are first in the differentiation lineage ordering, and are mainly involved in the regulation of osteoblastogenesis and inhibition of hematopoiesis; 2) preosteoblasts (LEPR<sup>high</sup>/VCAM1<sup>high</sup>) are differentiated from undetermined osteoblasts in the early stages of the lineage, and are primarily responsible for ECM organization during bone formation process as well as inducing hematopoiesis and modulating angiogenesis; 3) mature osteoblasts (IBSP<sup>high</sup>/BGALP<sup>high</sup>) arise at the terminal stages of cellular differentiation, and are crucial for bone mineralization.

Furthermore, in contrast to the results proposed by Tarkkonen et al.<sup>85</sup>, we demonstrated that there are systematic differences in transcriptional profiles at single-cell resolution between human and mouse osteoblasts, especially in early developmental stages. This finding highlights the

importance of conducting scRNA-seq studies with freshly isolated human osteoblasts, rather than relying solely on experiments in mice to infer the molecular mechanisms in humans.

Despite the novelty of this scRNA-seq study in freshly isolated human osteoblasts, an important limitation is that all the cells were collected from the femur head of one 31-year-old Chinese male subject with osteoarthritis and osteopenia. This might incur some bias in the osteoblast subpopulation identification and proportion estimation compared with healthy individuals. How would disease conditions affect cell subpopulations in their composition is an interesting topic awaiting further studies. Despite this potential limitation, our results provided the first necessary and valuable insights into the cellular heterogeneity of osteoblasts and a comprehensive and systematic understanding of the cell-intrinsic and cell-specific mechanisms, which may underlie bone metabolism and associated disorders.

## **Acknowledgement**

This research was benefited by grants from the National Institutes of Health (R01AR069055, U19AG055373, P20GM109036, R01AG061917), National Natural Science Foundation of China (Grant No. 81902277), National Key R&D Program of China (Grant No. 2017YFC1001100), Natural Science Foundation of Hunan Province (S2019JJQNJJ2093), Changsha Science and Technology project (kq1907153), Central South University (Grant Nos. 164990007, 2018zzts886), and Xiangya Clinical Big Data Project (xyyydsj9).

## **Author contributions**

YG wrote the main manuscript text and conducted major analysis; JY and LC collected the human sample and corresponding clinical information; XL, YC, and CZ performed the experiments; JG, HS, YPW, YPC and HWD did language proofreading; ZW, LJT, and YB prepared supplementary information and validated the results; the study was conceived, designed, initiated, directed, and supervised by HS, HMX, and HWD. All authors participated in the discussions of the project and reviewed and/or revised the manuscript.

## **Conflict of interest**

All authors have no conflicts of interest to declare.

## **Data availability**

The scRNA-seq data for primary osteoblasts from one human sample can be accessed with accession number under GSE147390 in GEO database. One previous scRNA-seq data of mice osteoblasts used in this study can be accessed with accession number of GSE108891.

## Reference

1. Caplan, A. I. Mesenchymal stem cells. *J. Orthop. Res.* **9**, 641–650 (1991).
2. Pittenger, M. F. *et al.* Multilineage potential of adult human mesenchymal stem cells. *Science* **284**, 143–147 (1999).
3. Owen, M. Marrow stromal stem cells. *J. Cell Sci. Suppl.* **10**, 63–76 (1988).
4. Yamaguchi, A., Komori, T. & Suda, T. Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and Cbfa1. *Endocr. Rev.* **21**, 393–411 (2000).
5. Maruotti, N., Corrado, A., Neve, A. & Cantatore, F. P. Bisphosphonates: effects on osteoblast. *Eur. J. Clin. Pharmacol.* **68**, 1013–1018 (2012).
6. Neve, A., Corrado, A. & Cantatore, F. P. Osteoblast physiology in normal and pathological conditions. *Cell Tissue Res.* **343**, 289–302 (2011).
7. Boskey, A. L. Matrix Proteins and Mineralization: An Overview. *Connect. Tissue Res.* **35**, 357–363 (1996).
8. Boskey, A. L. Biomineralization: Conflicts, challenges, and opportunities. *J. Cell. Biochem.* **72**, 83–91 (1998).
9. Rodan, G. A. & Martin, T. J. Role of osteoblasts in hormonal control of bone resorption--a hypothesis. *Calcif. Tissue Int.* **33**, 349–351 (1981).
10. Felix, R. *et al.* Rapid publication: Impairment of macrophage colony-stimulating factor production and lack of resident bone marrow macrophages in the osteopetrotic op/op Mouse. *J. Bone Miner. Res.* **5**, 781–789 (2009).
11. Lacey, D. L. *et al.* Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab. *Nat. Rev. Drug Discov.* **11**, 401–419 (2012).
12. Lacey, D. L. *et al.* Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. *Cell* **93**, 165–176 (1998).
13. Benayahu, D., Horowitz, M., Zipori, D. & Wientroub, S. Hemopoietic functions of marrow-derived osteogenic cells. *Calcif. Tissue Int.* **51**, 195–201 (1992).
14. Bilbe, G., Roberts, E., Birch, M. & Evans, D. B. PCR phenotyping of cytokines, growth factors and their receptors and bone matrix proteins in human osteoblast-like cell lines. *Bone* **19**, 437–445 (1996).
15. Ohtsuki, T. *et al.* A Proteoglycan Form of Macrophage Colony-Stimulating Factor That



- Binds to Bone-Derived Collagens and Can Be Extracted from Bone Matrix. *Biochem. Biophys. Res. Commun.* **190**, 215–222 (1993).
16. Blair, H. C. & Schlesinger, P. H. Purification of a stilbene sensitive chloride channel and reconstitution of chloride conductivity into phospholipid vesicles. *Biochem. Biophys. Res. Commun.* **171**, 920–925 (1990).
  17. Blair, H., Teitelbaum, S., Ghiselli, R., Science, S. G.- & 1989, undefined. Osteoclastic bone resorption by a polarized vacuolar proton pump. *science.sciencemag.org*
  18. Felix, R. *et al.* Production of hemopoietic growth factors by bone tissue and bone cells in culture. *J. Bone Miner. Res.* **3**, 27–36 (2009).
  19. GOWEN, M. *et al.* Production of Tumor Necrosis Factor by Human Osteoblasts is Modulated by Other Cytokines, but not by Osteotropic Hormones\*. *Endocrinology* **126**, 1250–1255 (1990).
  20. Hanazawa, S. *et al.* Spontaneous production of interleukin-1-like cytokine from a mouse osteoblastic cell line(MC3T3-E1). *Biochem. Biophys. Res. Commun.* **131**, 774–779 (1985).
  21. Horowitz, M. C., Coleman, D. L., Flood, P. M., Kupper, T. S. & Jilka, R. L. Parathyroid hormone and lipopolysaccharide induce murine osteoblast-like cells to secrete a cytokine indistinguishable from granulocyte-macrophage colony-stimulating factor. *J. Clin. Invest.* **83**, 149–157 (1989).
  22. Keeting, P. E. *et al.* Evidence for interleukin-1 $\beta$  production by cultured normal human osteoblast-like cells. *J. Bone Miner. Res.* **6**, 827–833 (2009).
  23. Marušić, A., Kalinowski, J. F., Jastrzebski, S. & Lorenzo, J. A. Production of leukemia inhibitory factor mRNA and protein by malignant and immortalized bone cells. *J. Bone Miner. Res.* **8**, 617–624 (2009).
  24. Schipani, E., Wu, C., Rankin, E. B. & Giaccia, A. J. Regulation of bone marrow angiogenesis by osteoblasts during bone development and homeostasis. *Front. Endocrinol. (Lausanne)*. **4**, (2013).
  25. Altschuler, S. J. & Wu, L. F. Cellular Heterogeneity: Do Differences Make a Difference? *Cell* **141**, 559–563 (2010).
  26. Guenther, H. L., Hofstetter, W., Stutzer, A., Mühlbauer, R. & Fleisch, H. Evidence for heterogeneity of the osteoblastic phenotype determined with clonal rat bone cells established from transforming growth factor-beta-induced cell colonies grown anchorage

- independently in semisolid medium. *Endocrinology* **125**, 2092–102 (1989).
27. Liu, F., Malaval, L. & Aubin, J. E. The mature osteoblast phenotype is characterized by extensive plasticity. *Exp. Cell Res.* **232**, 97–105 (1997).
  28. Hwang, B., Lee, J. H. & Bang, D. Single-cell RNA sequencing technologies and bioinformatics pipelines. *Experimental and Molecular Medicine* **50**, 1–14 (2018).
  29. Baryawno, N. *et al.* A Cellular Taxonomy of the Bone Marrow Stroma in Homeostasis and Leukemia. *Cell* **177**, 1915–1932.e16 (2019).
  30. Tikhonova, A. N. *et al.* The bone marrow microenvironment at single-cell resolution. *Nature* **569**, 222–228 (2019).
  31. Jilka, R. L. The relevance of mouse models for investigating age-related bone loss in humans. *J. Gerontol. A. Biol. Sci. Med. Sci.* **68**, 1209–17 (2013).
  32. Fujita, K., *et al.* Isolation and characterization of human osteoblasts from needle biopsies without in vitro culture. *Osteoporos Int* **25**, 887–95 (2014).
  33. Roforth, M. M. *et al.* Effects of age on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in humans. *Bone* **59**, 1–6 (2014).
  34. Fujita, K. *et al.* Effects of estrogen on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in postmenopausal women. *J. Clin. Endocrinol. Metab.* **99**, E81–8 (2014).
  35. Becht, E. *et al.* Dimensionality reduction for visualizing single-cell data using UMAP. *Nat. Biotechnol.* **37**, 38–47 (2019).
  36. Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. *Nat. Biotechnol.* **36**, 411–420 (2018).
  37. Meyer, M.B., N.A. Benkusky, and J. W. P. The RUNX2 cistrome in osteoblasts: characterization, down-regulation following differentiation, and relationship to gene expression. *J Biol Chem* **289**, 16016–31 (2014).
  38. Sandra Capellera-Garcia, A. *et al.* Defining the Minimal Factors Required for Erythropoiesis through Direct Lineage Conversion. (2016).  
doi:10.1016/j.celrep.2016.05.027
  39. Yuan, S. M.  $\alpha$ -Smooth muscle actin and ACTA2 gene expressions in vasculopathies. *Brazilian Journal of Cardiovascular Surgery* **30**, 644–649 (2015).

40. Hossain, M. M., Hwang, D. Y., Huang, Q. Q., Sasaki, Y. & Jin, J. P. Developmentally regulated expression of calponin isoforms and the effect of h2-calponin on cell proliferation. *Am. J. Physiol. - Cell Physiol.* **284**, (2003).
41. Wang, S. *et al.* S100A8/A9 in inflammation. *Frontiers in Immunology* **9**, (2018).
42. Ardi, V. C., Kupriyanova, T. A., Deryugina, E. I. & Quigley, J. P. Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. *Proc. Natl. Acad. Sci. U. S. A.* **104**, 20262–20267 (2007).
43. Limas, C. J. & Cohn, J. N. Alkaline phosphatase in vascular smooth muscle. *Nature New Biology* **245**, 53–55 (1973).
44. Liu, B. *et al.* A protocol for isolation and identification and comparative characterization of primary osteoblasts from mouse and rat calvaria. *Cell Tissue Bank.* **20**, 173 (2019).
45. Zhou, B. O., Yue, R., Murphy, M. M., Peyer, J. G. & Morrison, S. J. Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. *Cell Stem Cell* **15**, 154–168 (2014).
46. Akiyama, K. *et al.* Characterization of bone marrow derived mesenchymal stem cells in suspension. *Stem Cell Res. Ther.* **3**, 40 (2012).
47. Mertsch, S., Schurgers, L. J., Weber, K., Paulus, W. & Senner, V. Matrix gla protein (MGP): An overexpressed and migration-promoting mesenchymal component in glioblastoma. *BMC Cancer* **9**, 302 (2009).
48. Komori, T. Regulation of bone development and extracellular matrix protein genes by RUNX2. *Cell Tissue Res.* **339**, 189–195 (2010).
49. Xi, G., Rosen, C. J. & Clemmons, D. R. IGF-I and IGFBP-2 stimulate AMPK activation and autophagy, which are required for osteoblast differentiation. *Endocrinology* **157**, 268–281 (2016).
50. Maridas, D. E. *et al.* IGFBP-4 regulates adult skeletal growth in a sex-specific manner. *J. Endocrinol.* **233**, 131–144 (2017).
51. Li, C. *et al.* Tenascin C affects mineralization of SaOS2 osteoblast-like cells through matrix vesicles. *Drug Discov. Ther.* **10**, 82–87 (2016).
52. Guntur, A. R., Rosen, C. J. & Naski, M. C. N-cadherin adherens junctions mediate osteogenesis through PI3K signaling. *Bone* **50**, 54–62 (2012).
53. Doumas, S., Kolokotronis, A. & Stefanopoulos, P. Anti-inflammatory and antimicrobial

- roles of secretory leukocyte protease inhibitor. *Infection and Immunity* **73**, 1271–1274 (2005).
54. Choi, B. D. *et al.* Secretory leukocyte protease inhibitor promotes differentiation and mineralization of MC3T3-E1 preosteoblasts on a titanium surface. *Mol. Med. Rep.* **14**, 1241–1246 (2016).
  55. Cremasco, V. *et al.* Protein kinase C-delta deficiency perturbs bone homeostasis by selective uncoupling of cathepsin K secretion and ruffled border formation in osteoclasts. *J. Bone Miner. Res.* **27**, 2452–2463 (2012).
  56. El Amri, M., Fitzgerald, U. & Schlosser, G. MARCKS and MARCKS-like proteins in development and regeneration. *Journal of Biomedical Science* **25**, 1–12 (2018).
  57. Kim, H. J., Hong, J. M., Yoon, H. J., Yoon, Y. R. & Kim, S. Y. Carboxypeptidase E is a novel modulator of RANKL-induced osteoclast differentiation. *Mol. Cells* **37**, 685–690 (2014).
  58. Lammi, J. & Aarnisalo, P. FGF-8 stimulates the expression of NR4A orphan nuclear receptors in osteoblasts. *Mol. Cell. Endocrinol.* **295**, 87–93 (2008).
  59. Lammi, J., Rajalin, A. M., Hupponen, J. & Aarnisalo, P. Cross-talk between the NR3B and NR4A families of orphan nuclear receptors. *Biochem. Biophys. Res. Commun.* **359**, 391–397 (2007).
  60. Lee, M. K., Choi, H., Gil, M. & Nikodem, V. M. Regulation of osteoblast differentiation by Nurr1 in MC3T3-E1 cell line and mouse calvarial osteoblasts. *J. Cell. Biochem.* **99**, 986–994 (2006).
  61. Li, X. *et al.* Nur77 prevents excessive osteoclastogenesis by inducing ubiquitin ligase Cbl-b to mediate NFATc1 self-limitation. *Elife* **4**, (2015).
  62. Scholtysek, C. *et al.* NR4A1 Regulates Motility of Osteoclast Precursors and Serves as Target for the Modulation of Systemic Bone Turnover. *J. Bone Miner. Res.* **33**, 2035–2047 (2018).
  63. Zhao, L. *et al.* Smurf1 inhibits mesenchymal stem cell proliferation and differentiation into osteoblasts through JunB degradation. *J. Bone Miner. Res.* **25**, 1246–1256 (2010).
  64. Tokuzawa, Y. *et al.* Id4, a new candidate gene for senile osteoporosis, acts as a molecular switch promoting osteoblast differentiation. *PLoS Genet.* **6**, 1–15 (2010).
  65. Zeitouni, S. *et al.* Pharmaceutical induction of ApoE secretion by multipotent

- mesenchymal stromal cells (MSCs). *BMC Biotechnol.* **8**, 75 (2008).
66. Rosset, E. M. & Bradshaw, A. D. SPARC/osteonectin in mineralized tissue. *Matrix Biology* **52–54**, 78–87 (2016).
  67. Rutkovskiy, A., Stensløkken, K.-O. & Vaage, I. J. Osteoblast Differentiation at a Glance. *Med. Sci. Monit. Basic Res.* **22**, 95–106 (2016).
  68. Yang, X. *et al.* Osteogenic and angiogenic characterization of mandible and femur osteoblasts. *J. Mol. Histol.* **50**, 105–117 (2019).
  69. Dufourcq, P. *et al.* Secreted Frizzled-Related Protein-1 Enhances Mesenchymal Stem Cell Function in Angiogenesis and Contributes to Neovessel Maturation. *Stem Cells* **26**, 2991–3001 (2008).
  70. Choudhuri, R., Zhang, H. T., Donnini, S., Ziche, M. & Bicknell, R. An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. *Cancer Res.* **57**, 1814–1819 (1997).
  71. Lawler, J. W., Slayter, H. S. & Coligan, J. E. Isolation and characterization of a high molecular weight glycoprotein from human blood platelets. *J. Biol. Chem.* **253**, 8609–8616 (1978).
  72. Karar, J. & Maity, A. PI3K/AKT/mTOR Pathway in Angiogenesis. *Front. Mol. Neurosci.* **4**, (2011).
  73. Kang, D. W., Choi, K. Y. & Min, D. S. Functional regulation of phospholipase D expression in cancer and inflammation. *Journal of Biological Chemistry* **289**, 22575–22582 (2014).
  74. Sarwar, M., Du, X.-J., Dschietzig, T. B. & Summers, R. J. The actions of relaxin on the human cardiovascular system. *Br. J. Pharmacol.* **174**, 933–949 (2017).
  75. Neiva, K., Sun, Y. X. & Taichman, R. S. The role of osteoblasts in regulating hematopoietic stem cell activity and tumor metastasis. *Brazilian Journal of Medical and Biological Research* **38**, 1449–1454 (2005).
  76. Morrison, S. J. & Scadden, D. T. The bone marrow niche for haematopoietic stem cells. *Nature* **505**, 327–334 (2014).
  77. Zumkeller, W. & Burdach, S. The Insulin-Like Growth Factor System in Normal and Malignant Hematopoietic Cells. *Blood* **94**, 3653–3657 (1999).
  78. Stanley, E. R. & Chitu, V. CSF-1 receptor signaling in myeloid cells. *Cold Spring Harbor*

- Perspectives in Biology* **6**, (2014).
79. Zhang, C. C. & Lodish, H. F. Cytokines regulating hematopoietic stem cell function. *Current Opinion in Hematology* **15**, 307–311 (2008).
  80. Elkassar, N. & Gress, R. E. An overview of IL-7 biology and its use in immunotherapy. in *Journal of Immunotoxicology* **7**, 1–7 (NIH Public Access, 2010).
  81. Chen, C. Y. *et al.* Enhancement of CCL2 expression and monocyte migration by CCN1 in osteoblasts through inhibiting miR-518a-5p: Implication of rheumatoid arthritis therapy. *Sci. Rep.* **7**, 1–11 (2017).
  82. Gagnon, J. *et al.* IL-6, in Synergy with IL-7 or IL-15, Stimulates TCR-Independent Proliferation and Functional Differentiation of CD8 + T Lymphocytes . *J. Immunol.* **180**, 7958–7968 (2008).
  83. Park, I. K., Trotta, R., Yu, J. & Caligiuri, M. A. Axl/Gas6 pathway positively regulates FLT3 activation in human natural killer cell development. *Eur. J. Immunol.* **43**, 2750–2755 (2013).
  84. Vignudelli, T. *et al.* ZFP36L1 negatively regulates erythroid differentiation of CD34+ hematopoietic stem cells by interfering with the Stat5b pathway. *Mol. Biol. Cell* **21**, 3340–3351 (2010).
  85. Tarkkonen, K., Hieta, R., Kytölä, V., Nykter, M. & Kiviranta, R. Comparative analysis of osteoblast gene expression profiles and Runx2 genomic occupancy of mouse and human osteoblasts in vitro. *Gene* **626**, 119–131 (2017).
  86. Xie, H. *et al.* Estrogen receptor  $\alpha$ 36 mediates a bone-sparing effect of  $17\beta$ -estradiol in postmenopausal women. *J. Bone Miner. Res.* **26**, 156–168 (2011).
  87. Deng, F.-Y. *et al.* Genetic determination and correlation of body mass index and bone mineral density at the spine and hip in Chinese Han ethnicity. *Osteoporos. Int.* **17**, 119–124 (2006).
  88. Liang, X. *et al.* Assessing the genetic correlations between early growth parameters and bone mineral density: A polygenic risk score analysis. 301–306 (2018).  
doi:10.1016/j.bone.2018.08.021.Assessing
  89. Kanis, J. A., Melton, L. J. 3rd, Christiansen, C., Johnston, C. C. & Khaltaev, N. The diagnosis of osteoporosis. *J. Bone Miner. Res.* **9**, 1137–1141 (1994).
  90. Wu, X.-P. *et al.* Establishment of BMD reference plots and determination of peak BMD at

- multiple skeletal regions in mainland Chinese women and the diagnosis of osteoporosis. *Osteoporos. Int.* **15**, 71–79 (2004).
91. Blondel, V. D., Guillaume, J.-L., Lambiotte, R. & Lefebvre, E. *Fast unfolding of communities in large networks*. (2008).
  92. Yu, G., Wang, L. G., Han, Y. & He, Q. Y. ClusterProfiler: An R package for comparing biological themes among gene clusters. *Omi. A J. Integr. Biol.* **16**, 284–287 (2012).
  93. Trapnell, C. *et al.* The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. *Nat. Biotechnol.* **32**, 381–386 (2014).
  94. Stuart, T. & Satija, R. Integrative single-cell analysis. *Nat. Rev. Genet.* **20**, 257–272 (2019).
  95. Shi, Y. *et al.* Gli1 identifies osteogenic progenitors for bone formation and fracture repair. *Nat. Commun.* **8**, 1–12 (2017).

## Methods

### Study population

The clinical study was approved by the Medical Ethics Committee of Central South University and written informed consent was obtained from the study participant. The study population included one 31-year-old male with osteoarthritis and osteopenia (BMD T-score: 0.6 at lumbar vertebrae, -1.1 at total hip), who underwent hip replacement at the Xiangya Hospital of Central South University. The subject was screened with a detailed questionnaire, medical history, physical examination, and measured for bone mineral density (BMD) before surgery. Subjects were excluded from the study if they had preexisting chronic conditions which may influence bone metabolism including diabetes mellitus, renal failure, liver failure, hematologic diseases, disorders of the thyroid/parathyroid, malabsorption syndrome, malignant tumors, and previous pathological fractures<sup>86</sup>. The femur head was collected from the patient underwent hip replacement. The specimen was shortly stored in 4°C and transferred to the laboratory within 2 hours. The specimen was then processed within 24 hours after delivery.

### BMD measurement

BMD ( $\text{g}/\text{cm}^2$ ) was measured using DXA fan-beam bone densitometer (Hologic QDR 4500A, Hologic, Inc., Bedford, MA, USA) at the lumbar spine (L1 –L4) and the total hip (femoral neck and trochanter) as described previously by our group<sup>87,88</sup>. According to the World Health Organization definition<sup>89</sup> and the BMD reference established for Chinese population<sup>90</sup>, subjects with a BMD of 2.5 SDs lower than the peak mean of the same gender (T-score  $\leq -2.5$ ) were determined to be osteoporotic, while subjects with  $-2.5 < \text{T-score} < -1$  are classified as having osteopenia and subjects with T-score  $> -1.0$  are considered healthy.

### Isolation of osteoblasts

Osteoblasts were extracted from the human femur head based on the widely used dissociation protocols<sup>32</sup> with a few minor adjustments. Briefly, bone tissue samples were chopped into small fragments and washed twice with phosphate-buffered saline (PBS). These fragments, containing a mixture of cortical and trabecular bone, were then incubated with a highly purified, endotoxin-free type II collagenase (1 mg/ml, Cat: A004174-0001, Sangon Biotech, Shanghai, China) at 37.0°C for 30 mins and 60 mins in the first and second round of digestion respectively. After the



incubation, the solution was filtered through a 70  $\mu$ m filter and incubated with red blood cell lysis buffer (Thermo Fisher, Waltham, MA, USA) for 5 mins. The collected cells were washed twice with PBS.

### **Fluorescence-activated cell sorting (FACS) enrichment for osteoblasts**

Before FACS, collected cells were incubated with human CD31/34/45-PE (Cat:303106, Cat:343606, Cat:304008, BioLegend, San Diego, CA, USA), human ALPL-APC (Cat: FAB1448A, R&D Systems, Minneapolis, MN, USA), and 7-AAD (488 nm) antibody (R&D Systems, Minneapolis, MN, USA). FACS was performed on a BD FACS Aria II sorter (Becton-Dickinson, Franklin Lakes, NJ, USA), where dead cells and debris were excluded by forward versus side scatter (FSC/SSC), and live cells were further enriched by negative selection of 7-AAD. ALP+/CD45/34/31- cells were collected as osteoblasts (**Figure S1**)<sup>32</sup>. Gating schemes were established with fluorescence-minus-one (FMO) controls.

### **Single-cell RNA-seq (scRNA-seq) library preparation and sequencing**

scRNA-seq libraries were prepared using Single Cell 3' Library Gel Bead Kit V3 following the manufacturer's guidelines (<https://support.10xgenomics.com/single-cell-gene-expression/library-prep/doc/user-guide-chromium-single-cell-3-reagent-kits-user-guide-v3-chemistry>). Single cell 3' Libraries contain the P5 and P7 primers used in Illumina bridge amplification PCR. The 10x Barcode and Read 1 (primer site for sequencing read 1) were added to the molecules during the GEM-RT incubation. The P5 primer, Read 2 (primer site for sequencing read 2), Sample Index and P7 primer were added during library construction. The protocol is designed to support library construction from a wide range of cDNA amplification yields spanning from 2 ng to > 2  $\mu$ g without modification. All constructed single-cell RNA-seq libraries were sequenced on the Illumina Novaseq6000 platform with a sequencing depth of at least 100,000 reads per cell for a 150bp paired end (PE150) run.

### **Pre-processing of single-cell RNA-seq data**

We demultiplexed the cellular barcodes and aligned reads to the human transcriptome (GRCh38/hg38) using Cell Ranger 3.0 (<https://support.10xgenomics.com/single-cell-gene-expression/software/pipelines/latest/what-is-cell-ranger>). To create Cell Ranger-compatible

reference genomes, the references were rebuilt according to instructions from 10x Genomics (<https://www.10xgenomics.com>), which performs alignment, filtering, barcode counting and UMI counting. After that, a digital gene expression matrix (gene counts versus cells) was generated. For quality control, we removed the cells with <200 genes or > 5,000 genes detected, as well as cells where >15% of the transcripts were attributed to mitochondrial genes. The gene count matrix was converted to a Seurat object by the Seurat R package<sup>36</sup>. We normalized the filtered gene expression matrix by the *NormalizeData* function in Seurat R package, in which the number of UMIs of each gene was divided by the sum of the total UMIs per cell, multiplied by 10,000, and then transformed to log-scale.

### **Dimension reduction and osteoblastic clusters identification**

For data visualization and classification, we projected the normalized gene expression matrix on a two-dimensional panel. 2,000 genes with the highest dispersion (variance/mean) were selected for principle component analysis (PCA). The first 18 principle components (number of PCs was chosen based on standard deviations of the principal components, corresponding to the plateau region of "elbow plot") were used for uniform manifold approximation and projection (UMAP)<sup>35</sup> dimension reduction. After data visualization, we applied an unbiased graph-based clustering method<sup>91</sup> for clustering analysis. To identify the differentially expressed genes (DEGs) in each cluster, we used the Wilcoxon Rank-Sum test to find the genes showing significantly higher levels of expression (false discovery rate (FDR) < 0.05) in a specific cluster compared to the other clusters.

### **Pathway enrichment and trajectory inference analysis**

To investigate the biological processes and signaling pathways associated with each cluster (subtype), we performed gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) enrichment analysis for the genes identified as important cluster DEGs (avg\_FC > 1.2000) by using the *clusterProfiler* R package<sup>92</sup>. We then used the *Monocle 2* v2.8.0<sup>93</sup> R package to reconstruct the single-cell developmental trajectories in pseudo-time order. The principle of this analysis is to determine the pattern of the dynamic process experienced by the cell population and to order the cells along their developmental trajectory based on differences in the expression profiles of highly variable genes.

### **Cross-species scRNA-seq data integration**

One previous scRNA-seq dataset of mouse osteoblasts was acquired from GEO database under the accession numbers of GSE108891<sup>30</sup>. After acquiring the expression matrix of the osteoblasts in mice, we clustered them into three clusters (M1, M2, and M3), following the analysis pipeline published by Tikhonova et al.<sup>30</sup>. Next, we integrated the scRNA-seq data of mouse and human osteoblasts by canonical correlation analysis (CCA) using Seurat R package<sup>94</sup>. The biological variance of transcriptional profile across humans and mice was then evaluated based on the Spearman correlation of average gene expression between each of the datasets.

## Figure legends

### Figure 1. scRNA-seq Analysis of Human Osteoblasts

- (A) Study overview.
- (B) Three osteoblast clusters. UMAP visualization of 5,329 osteoblasts, colored by clustering.
- (C) Proportion of three osteoblast clusters. Colored by clustering.
- (D) Cluster signature genes. Violin plots showing the log-transformed normalized expression levels of the two most significant marker genes in clusters O1, O2, and O3, respectively.

### Figure 2. Cellular Functions of Osteoblast Subtypes in Bone Formation

- (A) Osteogenesis related genes expressed in clusters O1, O2, and O3, respectively.
- (B-D) GO enrichment for the three osteoblast subpopulations, O1, O2, and O3, respectively. The length of the bar indicates the gene ratio (number of DEGs enriched in the GO term / total number of DEGs). The color indicates the adjusted p values for enrichment analysis.
- (E) Bone formation related GO terms enriched in clusters O1, O2, and O3. The size of dot indicates the gene ratio. The color indicates the adjusted p-value for enrichment analysis.

### Figure 3. Trajectory Inference of Human Osteoblasts

- (A) Reconstructed cell differentiation trajectory of human osteoblasts. The upper-right trajectory plot in the square indicates the direction of pseudotime.
- (B) Expression levels (log-normalized) of indicated genes in the three osteoblast subtypes with respect to their pseudotime coordinates. The x-axis indicates the pseudotime, while the y-axis represents the log-normalized gene expression levels. The color corresponding to the three different osteoblast subsets. The loess regression was applied to fit the relationship between pseudotime and expression level.
- (C) Cell proportion changes in the three clusters based on the pseudotime coordinates. The x-axis is the pseudotime and the y-axis is the log-normalized gene expression level. We applied the loess regression to fit the relationship between the pseudotime and the cell proportion.

### Figure 4. Pre- and Undetermined Osteoblasts Regulate Angiogenesis and Hemopoiesis

- (A) Angiogenesis and hematopoiesis modulation related GO terms enriched in the three clusters. The x-axis represents the clusters and the y-axis is the GO terms related to the angiogenesis and

hematopoiesis regulation. The size of the dots indicates the gene ratio and the color indicates the adjusted p-values.

(B) Angiogenesis associated genes enriched in cluster O1. X-axis represents the three clusters and y-axis reflects log-normalized gene expression levels. The data are mean  $\pm$  standard deviation. Stars indicate the significance levels of the gene expression difference between two clusters by Wilcoxon signed-rank test. N.S., not significant, \*p-adjusted  $\leq$  0.05, \*\*p-adjusted  $\leq$  0.01, \*\*\* p-adjusted  $\leq$  0.005.

(C) Gene expression pattern in enriched pathways. Squares show enriched DEGs in the corresponding terms (rows). Color indicates the expression value of the DEGs (average logFC).

(D) Hemopoiesis factors enriched in clusters O1 and O3.


### **Figure 5. Integrated Cross-species Analysis Between Human and Mouse Osteoblasts**

(A) UMAP visualization of human and mouse osteoblast integration. The upper-left plot represents the three osteoblast clusters in mice, the upper-right plot indicates the three osteoblast subtypes in humans. The bottom plot represents the five clusters after the integration, colored by clusters. The middle-right is the integrated data colored by different species.

(B) Correlation of gene expression among different osteoblast datasets after CCA integration. Each dot represents an individual gene. Axes measure the average gene expression levels (logFC) in the indicated subject. Correlations were measured by Spearman correlation coefficients ( $R$ ) ( $p < 0.01$ ).


(C) Proportion of the human and mouse osteoblasts in each cluster after CCA integration, colored by different species. The x-axis represents five different clusters and y-axis indicates the proportion.

A




bioRxiv preprint doi: <https://doi.org/10.1101/2020.05.12.091975>; this version posted May 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.


B












C



D












A




B




C




D



A



B



C

